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The CC chemokine receptor 6 (CCR6) and its sole chemokine ligand CC chemokine 
ligand 20 (CCL20) display an emerging role in the coordination of humoral immune 
responses. Recent studies demonstrate a role of this chemokine axis in the migration 
of B cells to key immunological sites during an immune response, and facilitating the 
generation of high-quality antibodies. Very little, however, is known about CCL20 and 
its role in these functions. We undertook a preliminary investigation into the expression 
and function of CCL20 and demonstrate its well-noted upregulation in the spleen during 
immunization. Furthermore, we show that most follicular T helper (Tfh) cells can be 
CCR6+ and can produce CCL20. Surprisingly, CCL20 cannot only be found in the cyto-
plasm but also on the surface of these cells and their precursors. Analysis of T–B-cell 
conjugates revealed that mature Tfh cells, but not their precursors, are highly enriched 
in the conjugates. Further functional studies are needed to unravel the precise role of 
CCL20 in coordinating T and B cell interactions during the humoral immune response.
Keywords: T–B  cell communication, CC chemokine ligand 20, CC chemokine receptor 6, humoral immune 
response, T cells
INTRODUCTION
CC chemokine ligand 20 (CCL20) is emerging as an important mediator in the molecular orchestra-
tion of immunological homeostasis as well as the inflammatory and the humoral immune response 
(1, 2). CCL20 is expressed in endothelial cells (3), macrophages (4), and Th17 cells (5) and is upregu-
lated during inflammation (6). The only known receptor for CCL20 is the CC chemokine receptor 
6 (CCR6) which is found predominantly on dendritic cells (DC) (7), and on various lympocyte 
populations such as B cells, regulatory T cells (Tregs), Th17, and memory T cells (2). Mice geneti-
cally deficient for CCR6 demonstrate structural and functional deficits in mucosal immunity (8) 
highlighting the importance of this chemokine axis in homeostasis. Under inflammatory conditions, 
the regulation of CCR6 on DC, CD4+ T cell subpopulations, and B cells controls the migration of 
immune cells for correct positioning facilitating an efficient response (9, 10).
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The cellular expression of CCL20 and its putative function 
in the humoral immune response are still not understood. In 
comparison, its partner CCR6 on B cells has been characterized 
and its dynamic expression has been found to orchestrate B cells 
and the germinal center (GC) response. B  cells that leave the 
bone marrow to mature upregulate CCR6, and become highly 
responsive to CCL20—the precise reason of which has not been 
fully elucidated (9, 11). In CCR6-deficient mice, the GC response 
was quantitatively enhanced but at the expense of efficient 
and specific humoral immune responses (11, 12) and memory 
B  cell responses (10). This suggests an important role for the 
CCR6–CCL20 chemokine axis in humoral immunity. To further 
investigate these findings, we decided to investigate the potential 
role for CCL20 in coordinating T and B cell interactions.
MATERIALS AND METHODS
Mice and Immunizations
C57BL/6 WT and CCR6−/− mice on a C57BL/6 background (B6.
CCR6−/−) were sourced and generated as described (13). Animal 
experiments were approved by the University of Tasmania Animal 
Ethics Committee. Immunization was carried out by injecting 
1.0 × 108 sheep red blood cells (SRBC) suspended in sterile PBS 
intraperitoneally.
Polymerase Chain Reaction (PCR)
Spleens from sacrificed mice were removed and homogenized in 
liquid nitrogen. Spleens were then added to 1 mL of TriReagent 
(Sigma-Aldrich, NSW, Australia) and RNA extraction carried out 
as per manufacturer’s instructions. cDNA was synthesized from 
total RNA using Tetro cDNA synthesis kit (Bioline, Alexandria, 
NSW, Australia). Template cDNA was stored at −20°C until fur-
ther use. Quantitative real-time PCR was performed on cDNA 
templates using the SensiFAST SYBR No-Rox kit (Bioline). Results 
were normalized to β-actin (sense 5′- AGA GGG AAA TCG TGC 
GTG AC -3′ and anti-sense 5′- CAA TAG TGA TGA CCT GGC 
CGT -3′). The following primers were used: Ccr6 (sense 5′- TGT 
CCT CAC CCT ACC GTT CTG -3′ and anti-sense 5′- TAC AGG 
CCA GGA GCA GCA T -3′), and Bcl6 (sense 5′- CTG CAG ATG 
GAG CAT -3′ and anti-sense 5′- CGG CTG TTC AGG AAC -3′).
Antibodies
The following rat anti-mouse antibodies and conjugations were 
obtained from BioLegend (Australian Biosearch, WA, Australia), 
BD Biosciences (Sydney, NSW, Australia), or eBioscience (Sydney, 
NSW, Australia) and used for flow cytometry: B220-Biotin 
(clone RA3-6B2), CD19-APC Fire 750 (6D5), CCR6-PE (29-
2L17), CCR6-AF647 (140706), CD11b-PerCP-Cy5.5 (M1/70), 
CD11b-BV510 (M1/70), CD4-APC (RM4-5), CD4-PerCP Cy5.5 
(RM4-5), CD8α-PB (53-6.7), CXCR5-Biotin (2G8), CXCR5-
PerCP-Cy5.5 (2G8), PD-1-PE (J43), PD-1-PE-Cy7 (J43), TCR-
αβ-PB (HM3628, Thermo Fisher Scientific Australia, Soresby, 
VIC, Australia), hamster IgG1-λ isotype-PE (G235–2356), and 
rat IgG1-κ isotype-FITC (eBRG1). Cy5-conjugated streptavidin 
(Jackson Immuno Research, Pennsylvania, PA, USA) was used 
as secondary reagent. Unlabeled CCL20 (114906) was obtained 
from R&D Systems (Sydney, NSW, Australia) and labeled with 
DyLight 488 Microscale Antibody Labeling Kit (Thermo Fisher 
Scientific, Australia) according to the manufacturer’s instructions.
Flow Cytometry
Murine spleens were dissected and pushed through a 40 μm nylon 
cell strainer to obtain a single cell suspension. After washing, the 
cells were resuspended in 10 mL of red blood cell lysis buffer and 
left to incubate at room temperature for 10 min. For cells under-
going intracellular cytokine staining, 0.5 μL of 200 μg/mL PMA 
(Sigma-Aldrich) and 0.5 μL of 10 mM ionomycin (Thermo Fisher 
Scientific, Australia) were added to a 5 mL resuspension of the 
cells in RPMI medium (Thermo Fisher Scientific, Australia) and 
were incubated at 37°C for 1 h, 5% CO2. Following this, 1 μL of 
Golgi stop (BD Biosciences) (equivalent to 3.75 mM monensin) 
was added and the suspension incubated for further 3 h at 37°C.
Multicolor flow cytometry was performed on splenocytes 
using CyAn ADP and Gallios flow cytometers (Beckman Coulter, 
Inc., NSW, Australia). Post-acquisition analysis was performed 
using FlowJo v7.6 software (TreeStar, Inc., Ashland, OR, USA) 
and Kaluza 1.5a software (Beckman Coulter, Inc.). Fluorescent-
activated cell sorting (FACS) was performed using the MoFlo 
Astrios cell sorter (Beckman Coulter, Inc.) with a sorting accu-
racy >95%.
For surface-bound chemokine studies, cells were blocked 
with Fc-receptor block (BD Biosciences) for 30 min on ice and 
antibody staining performed under sodium azide-free condi-
tions. Fluorescent-minus-one and isotype controls were used 
to minimize non-specific binding and autofluorescence. To 
dissociate CCL20 from the surface cells were washed with acid 
as described (14). Briefly, cells were pelleted and resuspended in 
200 μL ice-cold acid buffer for 2 min. Samples were neutralized 
with 5× volumes of R10 medium and cells were washed twice 
with FACS buffer (2% FCS, 0,01% NaN3 in PBS). In the following 
experiments, Fc-block and surface staining were performed as 
indicated.
Statistics
Statistical analyses using the non-parametric two-tailed Mann–
Whitney U test were performed and graphs constructed using 
Prism software v5 (GraphPad Software). Graph columns repre-
sent median with error bars representing range. The alpha value 
was set at 0.05. In our figures these have been summarized as: 
*p < 0.05, **p < 0.01, ***p < 0.001.
RESULTS AND DISCUSSION
CCL20 Expression in Different Splenic 
Immune Cell Types
CC chemokine ligand 20 is an inflammatory chemokine that 
is upregulated by the pro-inflammatory cytokine TNF (3) or 
induced by TGF-β and IL-6, or IL-21 during TH17 cell differen-
tiation (5). To examine whether CCL20 is involved in humoral 
immune responses, we immunized mice with SRBC, known to 
trigger strong GC responses. Splenocytes from unchallenged 
mice expressed virtually no CCL20 (Figure S1A in Supplementary 
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Material). After immunization with SRBC splenocytes showed 
an upregulation of CCL20 mRNA in a time-dependent manner 
reaching approximately ninefold expression by day 7 (Figure S1A 
in Supplementary Material). Interestingly, Ccl20 has a very low-
constitutive expression in the spleen, relative to other organs such 
as Peyer’s patches (15) (Adrian Y. S. Lee and Heinrich Körner, 
unpublished data) suggesting a subordinate role in splenic 
immune homeostasis. In fact, the rapid and marked elevation of 
Ccl20 post-immunization suggests it has a very specific role in the 
inflammatory response. Therefore, we examined the expression 
of CCL20 in this organ for subsequent experiments.
To identify possible sources for splenic CCL20, we sorted day 5 
SRBC-immunized splenocytes and performed quantitative real-
time PCR on major cellular subpopulations found in the spleen: 
B cells (B220+TCR-β¯), CD4+ T cells (B220¯TCR-β+CD4+), CD8+ 
T  cells (B220¯TCR-β+CD8+), and miscellaneous CD11b+ cell 
populations (B220¯TCR-β¯CD11b+) which predominantly con-
sists of NK cells, splenic macrophages, and granulocytes (4, 16). 
An earlier study (10) demonstrated very low-constitutive Ccl20 
expression in the CD4+ T  cell compartment of the spleen and 
no expression in the CD8+ T cell or monocytic compartments. 
Our study, however, demonstrated Ccl20 mRNA highly expressed 
in CD11b+ cells after activation (Figure S1B in Supplementary 
Material). In comparison, total splenic Ccl20 expression was low 
suggesting a marked dilution by non-CCL20-producing cells, 
most likely the B cells. This is in line with early expression stud-
ies that found overall very low amounts of constitutive splenic 
Ccl20 compared with other organs (15). However, we show a 
substantially upregulated expression induced upon immuniza-
tion (Figure S1A in Supplementary Material) or challenge using 
bacterial lipopolysaccaride (data not shown).
Intracellular CCL20 Expression in Different 
Subsets of CD4+ T Cells
CC chemokine receptor 6, the CCL20 receptor, modulates GC 
reactions and antibody affinity maturation, which appears to be 
regulated by follicular T helper (Tfh) cells (17). Thus, the CCR6/
CCL20 axis might be involved in the GC response via Tfh cells (12) 
and we decided to focus our attention on CD4+ T cells, and specifi-
cally, Tfh cells. To initiate a strong humoral immune response, we 
used SRBC as a T cell-dependent antigen. We identified the Tfh 
population in spleen (Figure 1A) and sorted Tfh cells (defined as 
CD4+CXCR5hiPD-1hi) from SRBC-immunized mice (day 5 p.i.), 
an intermediate population Tfhint (CD4+CXCR5loPD-1lo) and the 
remaining CD4+ T  cells (non-Tfh cells; CD4+CXCR5−PD-1−) 
(Figure 1A). These non-Tfh cells comprise other T helper subsets 
(e.g., Th1), Tregs, and memory T cells including memory Tfh cells 
(18). The classic effector Tfh cells were significantly increased fol-
lowing immunization, confirming their activation (Figure S2 in 
Supplementary Material). To validate the quality of the isolated 
cell populations, we subjected sorted Tfh, Tfhint, and non-Tfh 
cells to qRT-PCR for Bcl6, demonstrating a non-significant trend 
toward highest mRNA expression in the Tfh cells, moderate 
expression in the intermediary population, and lowest expression 
in the non-Tfh cells (Figure 1B). The fact that we detected more 
Bcl6 in sorted CD4+TCRb+CXCR5+PD-1+ cells corroborates 
their identity as Tfh as shown previously (19). Similarly, we also 
show that mRNA expression of Ccr6 tends to be highest in Tfh 
cells (Figure  1C), which corresponds to protein expression as 
determined by flow cytometry (Figure 1D).
The canonical CD4+CCR6+ T cell population has been attrib-
uted to Th17  cells (20, 21); however, we show approximately 
90% of Tfh cells are positive for CCR6 (Figure  1E), consistent 
with our mRNA data for strong Ccr6 expression in this popula-
tion (Figure 1C). We performed intracellular cytokine staining 
and show that of the Tfhint population, a marked proportion of 
CCR6− cells are CCL20+, whereas very little CCR6+Tfhint cells are 
positive (Figure  1E). In contrast, the CCL20 expression is less 
marked in Tfh cells, being present in approximately 30% of cells 
(Figure 1E). The dominant intracellular CCL20 expression in the 
intermediary population (Figure 1F) is congruent to microarray 
data that demonstrated that Ccl20 is upregulated in intermediate 
population and down-regulated in Tfh cells (19). Interestingly, in 
a second study, CCL20 expression has also been described to be 
higher in Tfr cells than in regular Tfh cells (22).
Surface Expression of CCL20 on Tfh Cells
Since Tfh cells are known to form conjugates with CCR6+ 
B  cells, we examined surface expression of CCL20 on these 
cells. After eliminating autofluorescence (Figure S3 in Supple-
mentary Material) and non-specific binding through isotype and 
fluorescence-minus-one controls, we show that compared with 
non-Tfh cells, approximately 4% of Tfhint and Tfh cells show 
CCL20 on their surface (Figures  2A,B). To eliminate the pos-
sibility of the flow cytometric assay detecting bound CCL20 to 
CCR6, we used CCR6−/− mice and repeated the experiments. 
CCR6−/− mice similarly demonstrated surface CCL20 expres-
sion indicating that CCL20 is bound independent of CCR6 
(Figure 2B). The percentage of T cells with surface-bound CCL20 
did not differ significantly between parent populations of WT 
and CCR6−/− mice (Figures 2B,C).
To validate our differential flow cytometric detection of 
intracellular versus surface CCL20, we analyzed CCL20 expres-
sion on in  vitro-generated Th17  cells (23, 24). As expected, 
after activation, a major percentage of Th17 cells (circa 90% of 
Th17 cells) display a strong expression of intracellular CCL20 as 
published previously (5). However, additionally we were able to 
detect surface CCL20 on about 25% of Th17 cells (Figure S4 in 
Supplementary Material).
Chemokines are known to bind sulfated polysaccharides 
[glycosaminoglycans (GAGs)] found on cell surfaces (25). The 
presence of GAGs cause polymerization of chemokines, thereby 
increasing local concentration and facilitating chemokine-
receptor binding (26). In this case, the surface-bound CCL20 
likely functions to increase local concentration of the chemokine 
in order to create a concentration gradient for CCR6+ cells [hap-
totaxis (27)]—a likely candidate being partnering CCR6+ B cells 
to T cells as T–B cell conjugates.
The likely source of surface-bound CCL20 appears to be Tfhint 
and Tfh cells as indicated by protein (Figures 1E,F) and mRNA 
expression studies (19, 22). However, it is equally possible that 
CCL20 originates from other sources and becomes tethered on 
their surfaces. The closely related CCL19 and CCL21, for example, 
FIGURE 1 | Follicular T helper (Tfh) cells express CC chemokine receptor 6 (CCR6) and are positive for CC chemokine ligand 20 (CCL20) protein. (A) Gating 
strategy for Tfh cells isolated from splenocytes by ﬂuorescent-activated cell sorting. Non-Tfh cells (PD-1−CXCR5−) are marked in red, intermediary Tfh (Tfhint) 
(PD-1loCXCR5lo) cells are marked in blue, and Tfh cells (PD-1hiCXCR5hi) marked in green. mRNA expression of Bcl6 (B) and Ccr6 (C) normalized to Actb in the three 
isolated Tfh populations. One representative experiment is shown. Results are representative of two experiments with ﬁve to six mice each (Bcl6 and Ccr6) with 
5-day sheep red blood cells (SRBC)-immunized mice. Means between each column in (B,C) are not signiﬁcant (p > 0.05). (D) CCR6 protein expression in the three 
T cell populations via ﬂow cytometry using an isotype control (left panel). Mean ﬂuorescence intensity (MFI) of CCR6 is also provided (right panel). (E) Differential 
CCR6 and intracellular CCL20/isotype protein expression in the three splenic T cell populations via ﬂow cytometry in day 5 SRBC-immunized mice. CCL20 protein 
expression was quantiﬁed as MFIs and percentages (F). CCL20 gating is based on an isotype control. Representative panels from ﬁve independent experiments 
with two to ﬁve mice each. *p < 0.05, **p < 0.01, ***p < 0.001.
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could be detected on the luminal side of high-endothelial venules 
despite the fact that these cells do not seem to express mRNA 
for these chemokines. Instead, they rely on transcytosis of the 
ligands from the surrounding T  cell zone, presenting them on 
their surface to attract CCR7+ T  cells to secondary lymphoid 
organs (28, 29). Therefore, it is possible that the source of CCL20 
is the GC as both CCR6 and CCL20 are found in GC in lymphoid 
tissue (30) (Adrian Y. S. Lee and Heinrich Körner, unpublished 
data). To test whether CCL20 on Tfhint and Tfh cells is covalently 
expressed on the cell surface or bound via GAGs or others, we 
treated cells with an acid wash before staining. This experiment 
confirmed the increase in CCL20 expression proportional to 
Tfh differentiation, with acid wash leaving the frequency of 
CCL20 expressing cells unchanged (Figure  2C). Unexpectedly, 
FIGURE 2 | CC chemokine ligand 20 (CCL20) is found on the surface of splenic T cells. Surface-bound CCL20 was determined on T cells from sheep red  
blood cells-immunized WT and CCR6−/− mice at day 5 after immunization. Non-follicular T helper (Tfh) cells (CD11b−CD4hiTCRαβhiPD-1−CXCR5−), Tfhint 
(CD11b−CD4hiTCRαβhiPD-1loCXCR5lo), and Tfh cells (CD11b−CD4hiTCRαβhiPD-1hiCXCR5hi) were analyzed by ﬂow cytometry. (A) Representative ﬂow cytometry 
histograms of percent T cells with surface CCL20 in WT mice. The gate was made based on an isotype control. (B) Statistical analysis of the percentage of 
CCL20+ T cells in the total subpopulation comparing WT and CCR6−/− mice. Representative bar graph from two experiments with 10 mice of each genotype in 
total. (C) Percent surface CCL20 was analyzed in an independent experiment as well as CCL20 mean ﬂuorescence intensities (D). Cells were left untreated or 
stripped with acid buffer to remove non-speciﬁcally bound CCL20 from the surface. Flow cytometry plots representative for two experiments with 9 mice in total 
are displayed (E). *p < 0.05, **p < 0.01.
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FIGURE 3 | Follicular T helper (Tfh) cells represent the main CD4 subpopulation in T–B cell conjugates. Splenocytes from WT mice were analyzed at day 5 post-sheep 
red blood cells immunization for the composition of T–B cell conjugates. (A) Gating strategy for different CD4 subsets in single cells and in cell aggregates. (B) 
Conjugates are expressed as a percentage of total gated lymphocytes in WT and CCR6−/− mice. (C) The frequency of non-Tfh cells (PD-1−CXCR5−), Tfhint (PD-
1loCXCR5lo), and Tfh cells (PD-1hiCXCR5hi) within CD11b− CD4hi TCRαβhi are shown for singlets. (D) Using the same gates for non-Tfh cells, Tfhin and Tfh cells, the 
frequency of these three subpopulations is shown in CD11b−CD4+CD19+ conjugates and, as a control, in CD11b−CD4+CD19− conjugates (E), both pre-gated on cell 
aggregates in the forward-side-scatter. Shown are experiments with ﬁve mice {both genotypes; (B) or six mice [only wt; (A,C,D,E)]}. *p < 0.05, **p < 0.01.
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acid wash treatment enhanced the intensity of CCL20 staining 
(Figure 2D). Careful examination of the histograms showed that 
acid treatment removed the low-/intermediate surface CCL20 
surface expression but not the high-CCL20 expression in the 
CCL20 positive cell fraction (Figure  2E). Hence, high-CCL20 
surface expression represents covalently bound CCL20 and 
intermediate/low-expression represents CCL20 bound to GAG 
or others, but likely not in an autocrine or paracrine fashion to 
CCR6 (see Figure  2B). These data infer that a cell population 
with a low frequency of CCL20+ cells, for instance at a certain 
differentiation stage such as non-Tfh cells, can eventually provide 
as many CCL20 ligand binding sites as a population with a higher 
frequency of CCL20 positive cells. Cells displaying acid-sensitive 
CCL20 might serve as a mobile source of CCL20, thereby, pro-
viding spatio-temporal information during immune responses. 
Hence, even non-Tfh cells could have the capability of interacting 
with CCR6-expressing B cells; for instance at the entry point of 
the GC (12).
Tfh Cells in T–B Conjugates
To assess whether this surface-bound CCL20–CCR6 interaction 
is essential for the formation of T–B cell conjugates, we compared 
the formation of T–B cell conjugates in SRBC-immunized spleens 
from WT and CCR6−/− mice by flow cytometry. By gating on 
doublets and CD4+CD19+ cells, we determined a surrogate meas-
ure of T–B  cell conjugates (Figure  3A)—a method performed 
previously (31). We found a significantly higher proportion 
of CD4+CD19+ conjugates in CCR6−/− mice compared with 
WT mice, indicating that the CCR6–CCL20 chemokine axis 
is not essential for the formation of these T–B  cell conjugates 
(Figure 3B). This would be in accordance with the observation 
that mice deficient in CCR6 appeared to form more GCs in an 
accelerated fashion in the spleen than their WT counterparts (11). 
To determine which subpopulation of CCL20 expressing T cells 
(see Figures  2C,D) contributes to T–B-conjugate formation, 
we analyzed Tfh and Tfhint populations cells in CD11b-negative 
singlets or aggregates (Figure 3A, gating strategy). Whereas Tfh 
cells represent only 6–10% of CD4hiTCRhi cells within singlets 
or T cell duplets (Figures 3A,C), they are highly enriched over 
non-Tfh or Tfhint cells in T–B-conjugates (Figures  3D,E). The 
stability of the conjugates was addressed in control experiments 
using acid washing and treatment with EDTA. The proportion of 
T and B cells in conjugates was not changed by these treatments 
(data not shown).
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Thus, although the presence of CCR6 regulates T–B-conjugate 
formation negatively (Figure  3B), CCL20+ Tfh cells are most 
enriched in T–B-conjugates. Whether the B cells interacting with 
CCL20hi Tfh here represent light zone B cells that express CCR6 
(17) remains to be tested. In this case, the CCR6–CCL20 axis 
could be responsible for maintenance of the pairing between Tfh 
and cognate light zone B cell, thereby, contributing to the selec-
tion of high-affinity B  cells since CCR6−/− mice display poorer 
antibody quality production (11, 12).
On the other hand, our data show that Tfhint cells have a 
relatively high frequency of low-/intermediate CCL20 expressing 
cells (Figure 2E). It is known that T cells near the T–B border 
already express Bcl6 and are PD-1lo, preceding a Bcl6+PD-1hi 
phenotype (32), and therefore may correspond to our Tfhint. This 
Tfhint population appears to precede cognate B  cell interaction 
(33) and appears to be a necessary step in the selection of B cells 
and hence, formation of a GC (34). This notion together with 
our data implicates a fine-tuned CCR6–CCL20 axis in this critical 
conjugation, which might be modulated by the presentation of 
non-covalently CCL20 on the surface. Thus, the CCL20–CCR6 
axis likely functions at several GC checkpoints governing the 
efficacy of the GC reaction via B cells. It is tempting to speculate 
that two different mechanisms may act at the GC entry and at 
the GC selection point, depending on quantity and quality of 
surface-presented CCL20.
To conclude, we have shown that CCL20 is a chemokine that 
is produced by monocytes and T cells in the spleen. As subsets 
of the latter, Tfh and Tfhint cells are producers of CCL20 which 
is also tethered on their surfaces, an observation we have vali-
dated in vitro using Th17 cells. A likely function of this CCL20 
is in the role of coordinating cognate CCR6+ B cells to receive 
T cell help for the formation of antibodies. As optimal humoral 
immune responses rely on this critical T–B  cell interaction, 
further research into the role of the CCR6–CCL20 chemokine 
axis in this conjugation will be helpful in understanding subop-
timal immune responses and the pathogenesis of autoimmune 
disease.
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FIGURE S1 | CC chemokine ligand 20 (CCL20) mRNA becomes upregulated in 
splenocytes upon immunization and is highly expressed in splenic monocytes 
and T cells. (A) Time course of total spleen Ccl20 mRNA expression after SRBC 
intraperitoneal immunization. Graph is representative of six to eight mice at each 
timepoint. (B) Ccl20 mRNA expression in splenic cellular subpopulations. Day 5 
SRBC-immunized spleens were sorted for the four subpopulations. Intact 
splenocytes were used for “total spleen” and expression was measured relative 
to Actb. Data from three mice and one experiment are shown. NTC, no-template 
control; ND, not detected. **p < 0.01, ***p < 0.001.
FIGURE S2 | Upregulation of Tfh cells after mice immunization. B6 mice were 
immunized with intraperitoneal sheep red blood cells and splenocytes subjected 
to ﬂow cytometry. A clear upregulation of Tfh cells can be detected after 5 days 
of immunization. Shown here are representative ﬂow plots from ﬁve independent 
experiments.
FIGURE S3 | Method of gating out autoﬂuorescence in ﬂow cytometry. To 
eliminate the possibility of non-speciﬁc ﬂuorescence contributing to apparent  
cell surface chemokine expression, only cells negative for unutilized ﬂuorescent 
channels were gated in for analyses (sample plot shown).
FIGURE S4 | CC chemokine ligand 20 (CCL20) and Th17 cells. Assessment of 
CCL20 expression of Th17 cells in relation to cell proliferation was performed 
using ﬂow cytometry. Isolated CD4+ lymph node T cells were labeled with cell 
trace violet (CTV) and were activated in vitro with CD3/CD28 in the presence of  
a cocktail of TGF-β, IL-6, IL-23 in combination with anti-IL-4 and anti-IFN-γ for 
72 h following standard protocols. The expression of CCL20 on the surface  
(A) and intracellularly (B) was detected using a directly labeled anti-CCL20 mAb. 
The expression of IL-17 was independently veriﬁed using intracellular ﬂow 
cytometry and is not shown. A representative result is shown.
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